Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RX608 in patients with BRAF-mutant or BRAF-fusion glioma
CTR20263645Phase 2Active
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RX608 in glioma, sponsored by Suzhou Runxin Biotechnology. Started Sep 2026; status: active.
02
Drugs
RX608
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20263645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263645.